Skip to Content
Author: The BCW

Leave a Comment

Regeneron to Acquire Pharmaceutical Company for $250 Million

Regeneron Pharmaceuticals, Inc. continues to grow its research efforts in immuno-oncology with the announcement on Wednesday of an agreement to acquire Checkmate Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on proprietary technology to harness the power of the immune system to combat cancer. The proposed acquisition values Checkmate at a total equity value of approximately $250 million.

“As we continue to advance and expand our research efforts in immuno-oncology, the acquisition of Checkmate will add a promising new modality to Regeneron’s toolkit of potential approaches for difficult-to-treat cancers,” said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.

Checkmate’s lead investigational candidate is vidutolimod, which is administered into a tumor and is believed to induce and expand anti-tumor T cells and induce tumor regression as a monotherapy in patients whose tumors previously progressed on PD-1 checkpoint inhibition.

“The unique combination of a differentiated Toll-like receptor 9 with other antibody-based oncology agents may result in increased clinical benefit and provide new treatment options for patients in need. We look forward to welcoming the Checkmate team and their complementary scientific acumen to the Regeneron family,” said Schleifer.

“We are thrilled that Checkmate will become part of Regeneron, a biotechnology leader that shares our deep appreciation for science, hunger for ground-breaking discoveries and commitment to helping patients defeat cancer,” said Alan Bash, President and Chief Executive Officer of Checkmate which is based in Cambridge, Massachusetts.

“We believe that the data we have generated with vidutolimod positions Checkmate at the forefront of the innate immune activator field. It is our hope that Regeneron’s resources and expertise will help accelerate the development of vidutolimod and realization of the full potential of our virus-like particle (VLP) platform for immunotherapy,” said Art Krieg, M.D., Checkmate’s Founder and Chief Scientific Officer.

Similar News Items

The Business Council of Westchester’s Valley Bank Leadership Conversations welcomed New York Senate Majority Leader Andrea Stewart-Cousins on Thursday to share insights into her career and personal journey. Marsha Gordon, the BCW’s president and CEO, moderated the conversation at Kanopi in White Plains, where Stewart-Cousins recounted her diverse career path, including roles in customer service, […]

Read Article

If there is one subject virtually all business leaders agree on, it is that New York State’s energy landscape is changing. The challenge is that the paths forward are numerous, confusing and often are at odds with the practical realities of implementation costs and technological challenges. The Business Council of Westchester has spent the last […]

Read Article

The Business Council of Westchester’s Westchester Innovation Network (WIN) continues its mission of fostering innovation by facilitating a match between former WPHS graduate and recent Sacred Heart University graduate Michael Berlingo and seasoned executive coach Sunni Lampasso. This collaboration brings together the youthful energy and vision of Berlingo, CEO of Starteryou, with the wisdom and […]

Read Article

Become A Member

Join the county’s largest and most influential business organization today.

JOIN NOW!
The Business Council of Westchester is committed to helping businesses market, learn, advocate, and grow. Over 80 events and programs are offered every year, giving our members ample opportunity to connect and meet with businesses representatives in the Westchester community and beyond.
Back to top